Eli Lilly and Company logo

LLY

Eli Lilly and Company

PharmaceuticalsDrug Manufacturers$948B Market Cap

Pharmaceutical company focused on oncology, immunology, neuroscience. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.

Insider Sentiment
Based on recent trading activity
10%Bearish
Buy/Sell Ratio4% buys
BearishBullish
Eli Lilly and Company Live QuoteReal-time
$1347.11
+$40.42(+3.09%)1M
Day Range$1341.76 – $1372.05
Open$1362.38
Previous Close$1351.12
Volume3.50M
Key Financials & Valuation
Fundamental balance sheet & market metrics
HEALTHCARE
Market Cap$1.20T
P/E Ratio (TTM)44.9
Forward P/E27.8
EPS (TTM)$30.11
Price to Book30.6
Dividend Yield0.48%
Beta (Volatility)0.39
IndustryDRUG MANUFACTURERS - GENERAL
52-Week RangeCurrent: $1347.11 (80%)
Low: $846.81High: $1475.25
Wall Street Consensus
Strong Buy
Analyst Rating
4.8/ 5.0
Target Price
$1470.06+38.9% upside

Insider Buys

10

$86.30M

Insider Sales

46

$2.29B

Total Volume

$2.37B

100 transactions

Net Activity

$2.20B

Net selling

Proprietary Ratings
Calculated from Form 4 transactions
85CONFIDENCE

Sentiment Rating

Strong Accumulation

CEO Conviction Index

High Conviction Accumulation

Key Drivers

  • •Heavy distribution: sales represent 96% of total transaction value.
  • •Cluster buying: 10 unique insiders purchased shares, showing strong alignment.
  • •CEO buying activity detected. When chief executives put their own money at risk, it is historically a strong bullish signal.
  • •CFO buying activity detected. Statistical studies show CFO purchases have high predictive power due to their direct visibility into balance sheet details.
  • •Ultra-high accumulation: total purchase value exceeds $10M.
  • •Significant liquidation: total sale value exceeds $10M.
Score Methodology

The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:

  • +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
  • +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
  • +15CEO Buying: CEO committing own capital shows high conviction.
  • +10CFO Buying: CFO purchasing shares shows financial alignment.
Top Insiders
Most active traders
L
1

Lilly Endowment Inc

Former 10% Shareholder

0 buys37 sells

$2.25B total

M
2

Multiple Insiders

S - Sale Insiders

0 buys44 sells

$1.16B total

D
3

David Ricks

CEO

1 buys0 sells

$41.28M total

A
4

Afshin Mehra

CFO

1 buys0 sells

$40.49M total

B
5

Board Director

Dir

0 buys1 sells

$32.64M total

Trading History
LLY insider transactions from SEC Form 4 filings
DateInsiderTypeSharesPriceValueFiling

Oct 17, 2026

1 months ago

David Ricks

CEO

CEO
Buy40.8K$1012.16$41.28M

Oct 16, 2026

1 months ago

Afshin Mehra

CFO

CFO
Buy36.5K$1107.85$40.49M

Oct 7, 2026

1 months ago

Board Director

Dir

Director
Sell29.5K$1105.41$32.64M

Aug 17, 2026

3 months ago

Multiple Insiders

S - Sale Insiders

Insider
Sell54.8K$-6500.00$0

Aug 17, 2026

3 months ago

Jonsson Patrik

EVP, Pres, LLY Int'l

President
Sell6.5K$0.18$1K

Aug 10, 2026

3 months ago

Zakrowski Donald A

SVP, Finance, CAO

SVP
Sell2.0K$0.59$1K

Aug 10, 2026

3 months ago

Multiple Insiders

S - Sale Insiders

Insider
Sell3.3K$-2000.00$0

Aug 7, 2026

3 months ago

Hakim Anat

EVP, GC, Secretary

EVP
Sell5.0K$0.24$1K

Aug 7, 2026

3 months ago

Multiple Insiders

S - Sale Insiders

Insider
Sell50.6K$-5000.00$0

Jun 10, 2026

5 months ago

Yuffa Ilya

EVP, Pres, LLY USA, Global Cap

President
Sell2.5K$0.46$1K

Jun 10, 2026

5 months ago

Multiple Insiders

S - Sale Insiders

Insider
Sell29.8K$-2500.00$0

May 6, 2026

6 months ago

Multiple Insiders

S - Sale Insiders

Insider
Sell91.88M$-15828.00$0

May 6, 2026

6 months ago

Lilly Endowment Inc

Former 10% Shareholder

10% Owner
Sell15.8K$995.36$15.75M

Jan 7, 2026

10 months ago

Multiple Insiders

S - Sale Insiders

Insider
Sell91.90M$-292148.00$0

Jan 7, 2026

10 months ago

Lilly Endowment Inc

10%

10% Owner
Sell292.1K$0.11$33K

Jan 5, 2026

10 months ago

Lilly Endowment Inc

10%

10% Owner
Sell1.4K$0.78$1K

Jan 5, 2026

10 months ago

Multiple Insiders

S - Sale Insiders

Insider
Sell92.19M$-1390.00$0

Dec 29, 2025

10 months ago

Multiple Insiders

S - Sale Insiders

Insider
Sell92.19M$-3593.00$0

Dec 29, 2025

10 months ago

Lilly Endowment Inc

10%

10% Owner
Sell3.6K$0.30$1K

Dec 23, 2025

11 months ago

Lilly Endowment Inc

10%

10% Owner
Sell240$4.52$1K

Dec 24, 2025

11 months ago

Multiple Insiders

S - Sale Insiders

Insider
Sell92.19M$-2629.00$0

Dec 23, 2025

11 months ago

Multiple Insiders

S - Sale Insiders

Insider
Sell92.20M$-240.00$0

Dec 24, 2025

11 months ago

Lilly Endowment Inc

10%

10% Owner
Sell2.6K$0.41$1K

Nov 25, 2025

12 months ago

Multiple Insiders

S - Sale Insiders

Insider
Sell92.20M$-15632.00$0

Nov 25, 2025

12 months ago

Lilly Endowment Inc

10%

10% Owner
Sell147.1K$0.22$33K

Nov 25, 2025

12 months ago

Lilly Endowment Inc

10%

10% Owner
Sell15.6K$0.21$3K

Nov 24, 2025

12 months ago

Multiple Insiders

S - Sale Insiders

Insider
Sell92.36M$-142307.00$0

Nov 24, 2025

12 months ago

Lilly Endowment Inc

10%

10% Owner
Sell142.3K$0.05$6K

Nov 21, 2025

12 months ago

Lilly Endowment Inc

10%

10% Owner
Sell105.3K$0.17$18K

Nov 21, 2025

12 months ago

Multiple Insiders

S - Sale Insiders

Insider
Sell92.50M$-105326.00$0

Nov 20, 2025

12 months ago

Multiple Insiders

S - Sale Insiders

Insider
Sell92.61M$-37148.00$0

Nov 20, 2025

12 months ago

Lilly Endowment Inc

10%

10% Owner
Sell37.1K$0.17$6K

Nov 19, 2025

12 months ago

Multiple Insiders

S - Sale Insiders

Insider
Sell92.64M$-167526.00$0

Nov 19, 2025

12 months ago

Lilly Endowment Inc

10%

10% Owner
Sell167.5K$0.04$6K

Nov 18, 2025

12 months ago

Lilly Endowment Inc

10%

10% Owner
Sell60.2K$0.17$10K

Nov 18, 2025

12 months ago

Multiple Insiders

S - Sale Insiders

Insider
Sell92.81M$-60213.00$0

Nov 17, 2025

12 months ago

Multiple Insiders

S - Sale Insiders

Insider
Sell92.87M$-9886.00$0

Nov 17, 2025

12 months ago

Lilly Endowment Inc

10%

10% Owner
Sell9.9K$0.21$2K

Nov 14, 2025

12 months ago

Lilly Endowment Inc

10%

10% Owner
Sell178.3K$11.59$2.07M

Nov 14, 2025

12 months ago

Multiple Insiders

S - Sale Insiders

Insider
Sell92.88M$-178295.00$0

Nov 13, 2025

12 months ago

Multiple Insiders

S - Sale Insiders

Insider
Sell93.06M$-46606.00$0

Nov 13, 2025

12 months ago

Lilly Endowment Inc

10%

10% Owner
Sell46.6K$0.04$2K

Nov 12, 2025

12 months ago

Lilly Endowment Inc

10%

10% Owner
Sell305.0K$0.07$20K

Nov 12, 2025

12 months ago

Multiple Insiders

S - Sale Insiders

Insider
Sell93.11M$-305000.00$0

Nov 13, 2025

12 months ago

Zakrowski Donald A

SVP, Finance, CAO

SVP
Sell1.0K$1.01$1K

Nov 10, 2025

12 months ago

Lilly Endowment Inc

10%

10% Owner
Sell16.9K$972.52$16.41M

Nov 10, 2025

12 months ago

Multiple Insiders

S - Sale Insiders

Insider
Sell93.70M$-16869.00$0

Nov 11, 2025

12 months ago

Multiple Insiders

S - Sale Insiders

Insider
Sell93.41M$-283131.00$0

Nov 11, 2025

12 months ago

Lilly Endowment Inc

10%

10% Owner
Sell283.1K$974.70$275.97M

Nov 5, 2025

12 months ago

Multiple Insiders

S - Sale Insiders

Insider
Sell93.71M$-40432.00$0

Nov 5, 2025

12 months ago

Lilly Endowment Inc

10%

10% Owner
Sell40.4K$951.56$38.47M

Nov 5, 2025

12 months ago

Lilly Endowment Inc

10%

10% Owner
Sell179.0K$933.26$167.09M

Nov 4, 2025

12 months ago

Lilly Endowment Inc

10%

10% Owner
Sell526$910.72$479K

Nov 4, 2025

12 months ago

Multiple Insiders

S - Sale Insiders

Insider
Sell93.93M$-526.00$0

Nov 3, 2025

12 months ago

Lilly Endowment Inc

10%

10% Owner
Sell300.0K$888.83$266.65M

Nov 3, 2025

12 months ago

Multiple Insiders

S - Sale Insiders

Insider
Sell93.93M$-300000.00$0

Oct 31, 2025

12 months ago

Lilly Endowment Inc

10%

10% Owner
Sell301.3K$863.36$260.17M

Oct 31, 2025

12 months ago

Multiple Insiders

S - Sale Insiders

Insider
Sell94.23M$-301342.00$0

Oct 10, 2025

13 months ago

Multiple Insiders

S - Sale Insiders

Insider
Sell94.53M$-3658.00$0

Oct 10, 2025

13 months ago

Lilly Endowment Inc

10%

10% Owner
Sell3.7K$863.24$3.16M

Oct 9, 2025

13 months ago

Multiple Insiders

S - Sale Insiders

Insider
Sell94.54M$-10602.00$0

Oct 9, 2025

13 months ago

Lilly Endowment Inc

10%

10% Owner
Sell10.6K$852.49$9.04M

Oct 8, 2025

13 months ago

Lilly Endowment Inc

10%

10% Owner
Sell101.4K$850.28$86.23M

Oct 8, 2025

13 months ago

Multiple Insiders

S - Sale Insiders

Insider
Sell94.55M$-101420.00$0

Oct 7, 2025

13 months ago

Multiple Insiders

S - Sale Insiders

Insider
Sell94.65M$-26795.00$0

Oct 7, 2025

13 months ago

Lilly Endowment Inc

10%

10% Owner
Sell26.8K$848.01$22.72M

Oct 6, 2025

13 months ago

Lilly Endowment Inc

10%

10% Owner
Sell161.2K$850.22$137.04M

Oct 6, 2025

13 months ago

Multiple Insiders

S - Sale Insiders

Insider
Sell94.68M$-161183.00$0

Oct 3, 2025

13 months ago

Lilly Endowment Inc

10%

10% Owner
Sell192.4K$837.93$161.22M

Oct 3, 2025

13 months ago

Multiple Insiders

S - Sale Insiders

Insider
Sell94.84M$-192404.00$0

Oct 2, 2025

13 months ago

Lilly Endowment Inc

10%

10% Owner
Sell112.6K$821.55$92.50M

Oct 2, 2025

13 months ago

Multiple Insiders

S - Sale Insiders

Insider
Sell95.03M$-112596.00$0

Oct 1, 2025

13 months ago

Multiple Insiders

S - Sale Insiders

Insider
Sell95.14M$-215822.00$0

Oct 1, 2025

13 months ago

Lilly Endowment Inc

10%

10% Owner
Sell135.2K$794.15$107.36M

Oct 1, 2025

13 months ago

Lilly Endowment Inc

10%

10% Owner
Sell215.8K$821.47$177.29M

Sep 30, 2025

13 months ago

Lilly Endowment Inc

10%

10% Owner
Sell113.7K$763.39$86.79M

Sep 30, 2025

13 months ago

Multiple Insiders

S - Sale Insiders

Insider
Sell95.49M$-113694.00$0

Sep 19, 2025

14 months ago

Lilly Endowment Inc

10%

10% Owner
Sell23.7K$763.10$18.06M

Sep 19, 2025

14 months ago

Multiple Insiders

S - Sale Insiders

Insider
Sell95.61M$-23665.00$0

Sep 18, 2025

14 months ago

Multiple Insiders

S - Sale Insiders

Insider
Sell95.63M$-106626.00$0

Sep 18, 2025

14 months ago

Lilly Endowment Inc

10%

10% Owner
Sell106.6K$764.65$81.53M

Aug 28, 2025

15 months ago

Zakrowski Donald A

SVP, Finance, CAO

SVP
Sell1.0K$734.93$735K

Aug 28, 2025

15 months ago

Multiple Insiders

S - Sale Insiders

Insider
Sell5.6K$-1000.00$0

Aug 15, 2025

15 months ago

Montarce Lucas

EVP, CFO

CFO
Buy715$691.79$495K

Aug 15, 2025

15 months ago

Multiple Insiders

P - Purchase Insiders

Insider
Sell14.7K$715.00$10.50M

Aug 13, 2025

15 months ago

Multiple Insiders

P - Purchase Insiders

Insider
Sell55.8K$758.00$42.26M

Aug 13, 2025

15 months ago

Alvarez Ralph

Dir

Director
Buy758$660.25$500K

Aug 13, 2025

15 months ago

Van Naarden Jacob

EVP, Pres, Lilly Oncology

President
Buy1.0K$647.36$647K

Aug 12, 2025

15 months ago

Sulzberger Gabrielle

Dir

Director
Buy117$641.18$75K

Aug 11, 2025

15 months ago

Multiple Insiders

S - Sale Insiders

Insider
Sell26.3K$-1250.00$0

Aug 12, 2025

15 months ago

Multiple Insiders

P - Purchase Insiders

Insider
Sell677.0K$1632.00$1.10B

Aug 11, 2025

15 months ago

Yuffa Ilya

EVP, Pres, LLY USA, Global Cap

President
Sell1.3K$627.01$784K

Aug 12, 2025

15 months ago

Ricks David A

Pres, Chair,, CEO

CEO
Buy1.6K$644.77$1.05M

Aug 12, 2025

15 months ago

Skovronsky Daniel

EVP, CSO, Pres LRL, LLY Imm

President
Buy1.0K$634.41$634K

Aug 12, 2025

15 months ago

Fyrwald J Erik

Dir

Director
Buy1.6K$642.33$1.01M

Aug 8, 2025

15 months ago

Multiple Insiders

P - Purchase Insiders

Insider
Sell9.4K$200.00$1.88M

Aug 8, 2025

15 months ago

Jackson Jamere

Dir

Director
Buy200$639.56$128K

Jul 24, 2025

16 months ago

Multiple Insiders

S - Sale Insiders

Insider
Sell95.74M$-280000.00$0

Jul 24, 2025

16 months ago

Lilly Endowment Inc

10%

10% Owner
Sell280.0K$805.07$225.42M

May 27, 2025

18 months ago

Zakrowski Donald A

SVP, Finance, CAO

SVP
Sell1.0K$716.41$716K
Sector & Industry Benchmarks
Pharmaceuticals Comparison Overview
Industry Buy Conviction0%
LLY Buy Conviction4%
Industry Rank#0 of 1
Volume Contribution19896.1%
Total Industry Activity$11.93M

LLY has an insider buy conviction of 4%, compared to the Pharmaceuticals sector buy average of 0%.

Insider Trading Summary & Commentary
Automated executive transaction analysis for LLY

Over the last 90 days, corporate insiders at Eli Lilly and Company (LLY) engaged in a total of 100 transactions reported via SEC Form 4 filings. Among these, 10 were open-market purchases and 46 were sales. The total volume of insider trading reached $2.37B.

The net insider activity for LLY shows a net selling bias of $2.20B. This activity represents a 4% buy ratio, suggesting that insiders are currently bearish on the company's near-term outlook relative to recent history.

The most notable individual transaction was a Sale by Multiple Insiders (P - Purchase Insiders), who traded 677.0K shares valued at $1.10B on Aug 12, 2025.

Live Market News & Developments
Aggregated real-time headlines for Eli Lilly and Company (LLY)
6 updates

Eli Lilly (LLY) After ObesityWeek Is The Stock Still Undervalued

Yahoo Finance4h ago

Lilly vs. Pfizer: Which Drugmaker Has Stronger Growth Prospects?

The Globe and Mail7h ago

Was Eli Lilly Stock’s 45% Run Visible Early?

Trefis3d ago

Eli Lilly (NYSE:LLY): Strong Growth Paired With a High-Quality Technical Setup

ChartMill2d ago

Rhythm Pharmaceuticals gains on report Eli Lilly made $150/share offer with CVR (RYTM:NASDAQ)

Seeking Alpha3d ago

Eli Lilly hikes sales outlook, as CEO says there's room for 'dramatic' obesity market expansion

CNBC22d ago

Explore Peers in Drug Manufacturers

Compare insider activity and sentiment scores across similar organizations.

Related News & Analyst Reports

Read original insights and educational research covering Eli Lilly and Company and the Drug Manufacturers sector.

August 6, 2026

The AI Circular Valuation Bubble: Inside the Venture-Cloud Loop

An in-depth investigation into how technology giants and AI startups engage in circular capital flows, investing venture capital in exchange for cloud services and hardware, creating a closed-loop economy that artificially inflates valuations.

Read Analysis
March 20, 2026

Sequoia Capital and the Mechanics of Venture Lock-Up Extensions

Sequoia Capital pioneered the use of voluntary lock-up extensions to signal portfolio company confidence. This report analyzes the market-price impact of Sequoia extension announcements and whether they have historically justified the delay.

Read Analysis
February 26, 2026

The Role of Insider Trading in M&A: Deciphering the Pre-Merger Signals

M&A deals are the most fertile ground for illegal insider trading, and for legal cluster buys that signal a company is strategically attractive. This guide separates the legal signal from the illegal noise in M&A-adjacent Form 4 activity.

Read Analysis
January 23, 2026

Venture-Backed Biotech IPOs: Inside the 2026 Buying Spree

2026 saw a resurgence of venture-backed biotech IPOs, accompanied by unusually high post-lockup insider buying. This report documents the specific Form 4 cluster events, purchase sizes, and 90-day price performance across a dozen recent biotech offerings.

Read Analysis
September 15, 2025

Biotech Insider Buying: Analyzing Clinical Trial Catalysts

Biotech insiders walk a legal tightrope near trial readouts. This report identifies statistically significant buying clusters at small-cap biotechs 30-90 days before Phase 2 and Phase 3 data announcements.

Read Analysis
March 28, 2025

Deciphering Option Exercises (Code M) vs. Open Market Purchases (Code P)

Transaction code M (option exercise) is often mistaken for bullish conviction, but it usually means nothing. Learn why Code P open-market purchases are the only Form 4 entries that signal genuine insider belief.

Read Analysis

FAQs About Eli Lilly and Company Insider Trading

Answers to common questions regarding corporate filings and executive sentiment for LLY.

Based on SEC Form 4 disclosures, the Insider Confidence Score for LLY is currently 85/100, which reflects a strong accumulation bias. This calculation accounts for a total of 10 purchases and 46 sales by company executives over the last 90 days.

The CEO Conviction Index for LLY is rated as "High Conviction Accumulation". Executive buying is typically a strong vote of confidence as C-level leaders have the most intimate knowledge of their firm's prospects. Officer selling, on the other hand, is often routine and does not automatically signal operational weakness.

No. Insider tracking is a highly informative technical signal that indicates executive sentiment, but it should not be the sole basis for a transaction. Investors should combine this filing analysis with company financials, sector trends, and risk management criteria.